Emergency Medicine Doctors in Bossier City, LA Accepting Medicare

10 Emergency Medicine doctors found. Showing 1 - 10

Paul Brian Wheeler, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 436 Barrington Dr, Bossier City, LA 71112 Phone: 318-746-6260

Dr. Brandon P Smith, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Department Of Emergency Medicine, Bossier City, LA 71111 Phone: 318-212-7500    Fax: 318-212-7505

Kelly Wright Lambard, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Bossier City, LA 71111 Phone: 318-212-7000

John J Horan, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Bossier City, LA 71111 Phone: 318-212-7500    Fax: 318-212-7505

Steven E Holt, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Bossier City, LA 71111 Phone: 318-212-7500    Fax: 318-212-7505

Dr. William Bailey, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2239 Landau Ln, Bossier City, LA 71111 Phone: 318-742-0291

Dr. Tess B. Vanhoy, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2300 Hospital Dr, Bossier City, LA 71111 Phone: 318-212-7500

Dr. Harold Oscar Paden Jr., M.D. Emergency Medicine - Emergency Medical Services Medicare: Not Enrolled in Medicare Practice Location: 2125 Airline Dr, Bossier City, LA 71111 Phone: 318-773-9320

Michael Williams, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Bossier City, LA 71111 Phone: 318-212-7500    Fax: 318-212-7505

Dr. Joshua P Gaspard, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2400 Hospital Dr, Department Of Emergency Medicine, Bossier City, LA 71111 Phone: 318-212-7000

News Archive

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

Adolescent health programs receive only a tiny share of international aid, finds research

Melbourne's Murdoch Children's Research Institute, in partnership with Harvard Medical School, has discovered that adolescent health programs across the developing world receive only a tiny share of international aid, even though young people make up 30 percent of the population of low-income countries.

Survey: Only half of primary care physicians aware of Complete Emollient Therapy for managing patients with eczema

The results of a new survey have found that only half of primary care practitioners are aware of Complete Emollient Therapy as a principle for managing patients with dry skin/eczema.

Research shows basophils are key players in lung development

Lungs are vital organs required for the uptake of oxygen in exchange for carbon dioxide. However, the enormous complexity of the respiratory organ is often underestimated and deserves a closer look: A broad range of specialized cells work closely together to ensure the proper functioning of the lung and provide the vital gas exchange.

Comedy helps kids deal with pain for longer periods of time

Watching comedy shows helped children tolerate pain for longer periods of time, suggesting that humorous distraction could be used in clinical settings to help children and adolescents better handle painful procedures, according to a study which teamed UCLA's Jonsson Comprehensive Cancer Center with the nonprofit organization Rx Laughter.

Read more Medical News

› Verified 8 days ago